Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas

Mol Med Rep. 2015 Sep;12(3):4298-4304. doi: 10.3892/mmr.2015.3976. Epub 2015 Jun 22.

Abstract

Patients with skull base chordomas have a poor prognosis, and the role of the protein expression of brachyury in chordomas remains to be fully elucidated. The present study used immunohistochemistry to analyze 57 cases of skull base chordoma, and analyzed the clinical data of the patients. The results demonstrated that the protein expression of brachyury was negative in 8.8% (5/57) of the cases. The weak/positive, positive and strong/positive rates were 5.3% (3/57), 21.1% (12/57) and 64.9% (37/57), respectively. The association between the expression of brachyury and recurrence was not statistically significant. Kaplan‑Meier analysis revealed that the degree of surgery, rather than the expression of brachyury, was associated with tumor recurrence (P=0.001). In conclusion, the results of the present study demonstrated that the expression of Brachyury offers a sensitive marker, but not a risk factor, for skull base chordomas, and radical surgery is recommended.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers, Tumor / metabolism*
  • Chordoma / diagnosis
  • Chordoma / metabolism*
  • Chordoma / mortality
  • Chordoma / surgery
  • Female
  • Fetal Proteins / metabolism*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / metabolism
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / prevention & control
  • Prognosis
  • Proportional Hazards Models
  • Skull Base Neoplasms / diagnosis
  • Skull Base Neoplasms / metabolism*
  • Skull Base Neoplasms / mortality
  • Skull Base Neoplasms / surgery
  • T-Box Domain Proteins / metabolism*
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Fetal Proteins
  • T-Box Domain Proteins
  • Brachyury protein